| 24.545 -0.035 (-0.14%) | 04-24 10:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.72 | 1-year : | 33.75 |
| Resists | First : | 27.16 | Second : | 28.89 |
| Pivot price | 25.39  |
|||
| Supports | First : | 24.35 | Second : | 20.25 |
| MAs | MA(5) : | 24.71 |
MA(20) : | 25.64 |
| MA(100) : | 27.42 |
MA(250) : | 27.54 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 14.8 |
D(3) : | 12.3 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 36.91 | Low : | 19.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DOCS ] has closed above bottom band by 23.2%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.19 - 25.31 | 25.31 - 25.43 |
| Low: | 24.2 - 24.35 | 24.35 - 24.5 |
| Close: | 24.3 - 24.54 | 24.54 - 24.78 |
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Wed, 24 Apr 2024
DiCello Levitt LLP Announces Investor Lawsuit Filed Against Doximity, Inc. (NYSE: DOCS) and Lead Plaintiff Deadline - GlobeNewswire
Tue, 23 Apr 2024
Doximity Becomes Oversold (DOCS) - Nasdaq
Tue, 23 Apr 2024
DOCS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Doximity, Inc. Investors to Secure Counsel ... - Business Wire
Tue, 23 Apr 2024
6 Analysts Assess Doximity: What You Need To Know - Doximity (NYSE:DOCS) - Benzinga
Tue, 23 Apr 2024
DOCS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Doximity, Inc. Investors with ... - AccessWire
Mon, 22 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCS - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 122 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 9,130 (K) |
| Shares Short P.Month | 7,360 (K) |
| EPS | 0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.63 |
| Profit Margin | 29.3 % |
| Operating Margin | 43.6 % |
| Return on Assets (ttm) | 9.9 % |
| Return on Equity (ttm) | 15.3 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.83 |
| EBITDA (p.s.) | 1.39 |
| Qtrly Earnings Growth | 50 % |
| Operating Cash Flow | 167 (M) |
| Levered Free Cash Flow | 134 (M) |
| PE Ratio | 36.94 |
| PEG Ratio | 2.6 |
| Price to Book value | 5.33 |
| Price to Sales | 6.45 |
| Price to Cash Flow | 18.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|